Clinical trials: Alcohol-associated Liver Disease
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Alcoholic Hepatitis
Bovine Colostrum In The Treatment Of Severe Alcohol-Associated Hepatitis
Severe Alcohol-associated hepatitis, is associated with significant morbidity and mortality.1,2 Of the various treatment modalities evaluated for treatment of Severe Alcoholic hepatitis, corticosteroids have been the most…
- Trial name
- BASH (NCT07898761)
- Testing
- Bovine Colostrum Preparation
- Where
- India
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Dayanand Medical College and Hospital
Alcohol Hepatitis
A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)
A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects with Moderate Alcohol Associated Hepatitis (Part 1)
- Trial name
- NCT06685692
- Testing
- ADX-629
- Where
- 6 sites in United States
- Volunteers
- 4 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Hepatitis
Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)
The primary purpose of this study is to evaluate the safety and efficacy of larsucosterol, as determined by transplant-free survival through Day 90 in participants with severe alcohol-associated hepatitis (AH) with pre-treatment…
- Trial name
- NCT07428538
- Testing
- Larsucosterol
- Where
- 92 sites in United States
- Volunteers
- 350 people
- Sponsor
- Bausch Health Americas, Inc.
Alcohol Use Disorder, Alcohol Associated Liver Disease
A Digital Pill System to Measure and Support Acamprosate Adherence in Individuals With Alcohol Associated Liver Disease
This study seeks to develop and test a novel digital pill system (DPS) that measures real-time medication ingestion and pairs it with a cognitive behavioral therapy (CBT)-based intervention to provide personalized, data-driven…
- Conditions
- Alcohol Use Disorder, Alcohol Associated Liver Disease, Medications for Alcohol Use Disorder, Behavioral Medicine
- Trial name
- NCT07553377
- Testing
- AcamproSync
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yale University
Alcohol Use Disorder, Alcohol-associated Liver Disease
Pomegranate Dietary Supplements in AUD and ALD
The goal of this project is to determine an individual's ability to generate active gut microbial metabolites called urolithins upon consumption of pomegranate dietary supplements.
- Conditions
- Alcohol Use Disorder, Alcohol-associated Liver Disease, Alcoholic Cirrhosis, Healthy
- Trial name
- NCT07678567
- Testing
- Pomegranate Dietary Ssupplement
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- University of Louisville
Liver Cirrhosis
Apixaban to Prevent Decompensation of Early Liver Cirrhosis Trial
Liver disease is the only common cause of death that is increasing in numbers. Once people develop severe scarring (cirrhosis), there are no medications proven to help them live longer, healthier lives.
- Trial name
- APEACH (NCT07726693)
- Testing
- Apixaban 2.5 mg twice daily
- Volunteers
- 1,142 people
- Sponsor
- University College, London
Steatosis of Liver
Impact of Steatotic Liver Disease Associated With Metabolic Dysfunction (MASLD) on Frailty, Cognition, and Quality of Life. A Gender-sensitive Approach Towards a Comprehensive and Equitable Perspective.
The goal of this observational study is to determine the differences in the prevalence, characteristics and evolution of frailty between men and women diagnosed with MASLD, and to establish its relationship with clinical…
- Trial name
- MASLD (NCT07652892)
- Where
- 2 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Alcohol-Related Liver Disease
A Large Language Model-based Chatbot for Alcohol Reduction in Patients With Metabolic Alcohol-Related Liver Disease
The goal of this pilot randomized controlled trial is to evaluate the trial feasibility and acceptability of LLM-based chatbot for reducing alcohol use among patients with metabolic alcohol-related liver disease.
- Trial name
- NCT07450144
- Testing
- LLM-based chatbot, Telephone counseling, Alcohol Brief Intervention
- Where
- Hong Kong
- Volunteers
- 50 people
- Sponsor
- The University of Hong Kong
Non-alcoholic Fatty Liver Disease
A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
This study is designed to study the pharmacokinetic (PK) and safety profiles of a single dose of efimosfermin alfa in participants with varying degrees of Hepatic Impairment (HI) (assessed by Child-Pugh score) due to steatotic…
- Trial name
- NCT07358546
- Testing
- Efimosfermin alfa
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline
Alcohol Use Disorder, Liver Diseases
Implementation of a Digital Clinic for Alcohol-associated Liver Disease and Alcohol Use Disorder (DALC)
The purpose of this study is to determine whether a multidisciplinary digital clinic will improve health outcomes, reduce costs, increase access, and improve provider satisfaction.
- Trial name
- DALC (NCT06319222)
- Testing
- DALC Digital Clinic
- Where
- 2 sites in United States
- Volunteers
- 145 people
- Sponsor
- Mayo Clinic
Steatotic Liver Disease of Mixed Origin (MetALD)
Team Science (The Liver Health Study)
Liver damage from alcohol intake and weight-related behaviors is preventable and treatable only through lifestyle changes. This mixed-methods randomized controlled trial compares standard and enhanced approaches to screening…
- Trial name
- NCT06924281
- Testing
- Brief motivational interviewing with personalized feedback, Brief motivational interviewing with standard health information
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Brown University
Alcohol-associated Fatty Liver Disease
High-Plant-Protein-Diet or High-Animal-Protein-Diet for Improving Alcoholic Fatty Liver Disease
Alcohol-associated liver disease (ALD) is a major cause of mortality from advanced liver disease, accounting for 47.9% of cirrhosis-related deaths and 30% of hepatocellular carcinoma-related deaths annually.
- Trial name
- NCT07897981
- Testing
- whey protein powder, soy protein powder
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Li Lab,MD
Alcoholic Hepatitis
Short Course Steroids in Alcohol Associated Hepatitis
Alcohol-associated hepatitis (AAH) is one of the most severe manifestations of the spectrum of alcohol related liver disease (ARLD), with high morbidity and mortality.
- Trial name
- STASHII (NCT06919458)
- Testing
- Prednisolone 40 mg
- Where
- 2 sites in India
- Volunteers
- 151 people
- Sponsor
- Asian Institute of Gastroenterology, India
Alcohol Use Disorder, Alcohol-associated Liver Disease
Implementation Facilitation Pilot for Alcohol Use Disorder (AUD) in Alcohol-associated Liver Disease (ALD)
The goal of this project is to improve provision of integrated medications for alcohol use disorder (MAUD) with brief counseling for patients with alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) in…
- Trial name
- NCT07525258
- Testing
- Implementation Intervention
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Yale University
Liver Disease; Alcohol-Related, Cirrhosis
Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease
The purpose of this research study is to test the safety, tolerability, and effectiveness of the capsules that contain bacteria from healthy individuals when used to treat alcohol craving and drinking.
- Conditions
- Liver Disease; Alcohol-Related, Cirrhosis, Alcohol Use Disorder
- Trial name
- IMPACT (NCT05548452)
- Testing
- Intestinal Microbiota Transplant (IMT) Capsules
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Virginia Commonwealth University
Alcohol-associated Liver Disease
RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in subjects with ALD.
- Trial name
- NCT07009860
- Testing
- Pemvidutide
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 121 people
- Sponsor
- Altimmune, Inc.
Alcoholic Liver Disease
Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease
A Phase I clinical trial to determine the safety and tolerability of an anti-IL23 antibody for the treatment of patients with alcoholic liver disease
- Trial name
- NCT04736966
- Testing
- Guselkumab 30mg, Guselkumab 70mg, Guselkumab 100mg
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of California, San Diego
Alcohol-related Liver Disease, Liver Diseases
Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
The purpose of this trial is to see if providing patients with alcohol-related liver disease with tailored alcohol use treatment options will increase engagement with treatment and correct possible misconceptions.
- Trial name
- ENGAGE-ALD (NCT06269510)
- Testing
- ENGAGE-ALD Application (APP), Treatment Facilitation bundle, Enhanced Usual Care
- Where
- United States
- Volunteers
- 268 people
- Sponsor
- Henry Ford Health System
Steatotic Liver Disease, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Long-term Follow-up to Determine Outcome in Liver Disease (LOVE Study)
The rational to conduct the LOVE study builds on the lack of available data on outcomes in steatotic liver disease in well characterized patients over a time frame of several years.
- Conditions
- Steatotic Liver Disease, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Steatotic Liver Disease of Mixed Origin (MetALD), ALD - Alcoholic Liver Disease
- Trial name
- LOVE (NCT06907563)
- Where
- 4 sites in France, Germany and 2 more
- Volunteers
- 30,000 people
- Sponsor
- Universität des Saarlandes